我国将强化病毒性肝炎医源性感染管理,实施综合干预措施

2018-07-28 王宾 新华社

新华社北京7月27日电 7月28日是“世界肝炎日”,我国的宣传主题是“积极预防,主动检测,规范治疗,全面遏制肝炎危害”。国家卫生健康委员会疾控局有关负责人表示,我国将多措并举持续做好病毒性肝炎防治工作。在近日举行的“2018年世界肝炎日宣传大会”上,世界卫生组织驻华代表处专家说,病毒性乙型肝炎和丙型肝炎属于主要卫生挑战。至少有60%的肝癌病例因没有及时检测和治疗病毒性乙型肝炎和丙型肝炎所致。据了

新华社北京7月27日电 7月28日是“世界肝炎日”,我国的宣传主题是“积极预防,主动检测,规范治疗,全面遏制肝炎危害”。国家卫生健康委员会疾控局有关负责人表示,我国将多措并举持续做好病毒性肝炎防治工作。

在近日举行的“2018年世界肝炎日宣传大会”上,世界卫生组织驻华代表处专家说,病毒性乙型肝炎和丙型肝炎属于主要卫生挑战。至少有60%的肝癌病例因没有及时检测和治疗病毒性乙型肝炎和丙型肝炎所致。

据了解,我国持续重视病毒性肝炎防治工作,实施以预防接种为主的综合防控策略。乙肝疫苗和甲肝疫苗已纳入国家免疫规划程序。数据显示,2014年1-4岁的人群乙肝病毒表面抗原流行率是0.32%,和2006年相比下降66.67%。

此外,相关医疗、药品保障政策不断完善。我国逐步将抗病毒治疗药品纳入基本医保范畴,建立抗病毒治疗药品审批绿色通道,并开展药品价格谈判。

“降低育龄妇女、静脉吸毒者、医疗相关感染者等乙肝病毒传播和感染高危群体的病毒携带率,是我国病毒性肝炎防治持续面临的挑战。”中国工程院院士、北京大学医学部教授庄辉说。

针对可能传播病毒性肝炎的危险因素,下一步我国将强化医源性感染管理,加强医疗卫生机构医院感染控制管理和监督检查,加强传播病毒性肝炎重点人群防控,实施综合干预措施等。

“2018年世界肝炎日宣传大会”由国家卫生健康委员会疾控局主办、中国肝炎防治基金会承办。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634539, encodeId=a0a31634539c1, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Fri Jun 28 00:01:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986372, encodeId=6ed419863e225, content=<a href='/topic/show?id=f3f1e0930ed' target=_blank style='color:#2F92EE;'>#病毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70930, encryptionId=f3f1e0930ed, topicName=病毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 14 18:01:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032116, encodeId=31c720321162f, content=<a href='/topic/show?id=9952e912290' target=_blank style='color:#2F92EE;'>#综合干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79122, encryptionId=9952e912290, topicName=综合干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 18 04:01:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336344, encodeId=3e0833634444, content=加强病毒性肝炎的管理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 11:12:43 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334830, encodeId=a31a33483062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Sun Jul 29 06:49:53 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634539, encodeId=a0a31634539c1, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Fri Jun 28 00:01:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986372, encodeId=6ed419863e225, content=<a href='/topic/show?id=f3f1e0930ed' target=_blank style='color:#2F92EE;'>#病毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70930, encryptionId=f3f1e0930ed, topicName=病毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 14 18:01:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032116, encodeId=31c720321162f, content=<a href='/topic/show?id=9952e912290' target=_blank style='color:#2F92EE;'>#综合干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79122, encryptionId=9952e912290, topicName=综合干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 18 04:01:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336344, encodeId=3e0833634444, content=加强病毒性肝炎的管理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 11:12:43 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334830, encodeId=a31a33483062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Sun Jul 29 06:49:53 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-11-14 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634539, encodeId=a0a31634539c1, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Fri Jun 28 00:01:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986372, encodeId=6ed419863e225, content=<a href='/topic/show?id=f3f1e0930ed' target=_blank style='color:#2F92EE;'>#病毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70930, encryptionId=f3f1e0930ed, topicName=病毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 14 18:01:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032116, encodeId=31c720321162f, content=<a href='/topic/show?id=9952e912290' target=_blank style='color:#2F92EE;'>#综合干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79122, encryptionId=9952e912290, topicName=综合干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 18 04:01:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336344, encodeId=3e0833634444, content=加强病毒性肝炎的管理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 11:12:43 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334830, encodeId=a31a33483062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Sun Jul 29 06:49:53 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1634539, encodeId=a0a31634539c1, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Fri Jun 28 00:01:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986372, encodeId=6ed419863e225, content=<a href='/topic/show?id=f3f1e0930ed' target=_blank style='color:#2F92EE;'>#病毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70930, encryptionId=f3f1e0930ed, topicName=病毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 14 18:01:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032116, encodeId=31c720321162f, content=<a href='/topic/show?id=9952e912290' target=_blank style='color:#2F92EE;'>#综合干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79122, encryptionId=9952e912290, topicName=综合干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 18 04:01:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336344, encodeId=3e0833634444, content=加强病毒性肝炎的管理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 11:12:43 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334830, encodeId=a31a33483062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Sun Jul 29 06:49:53 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-08-04 liumin1987

    加强病毒性肝炎的管理。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1634539, encodeId=a0a31634539c1, content=<a href='/topic/show?id=b6974881243' target=_blank style='color:#2F92EE;'>#干预措施#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48812, encryptionId=b6974881243, topicName=干预措施)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a51a22195904, createdName=xiaoyang_ambs, createdTime=Fri Jun 28 00:01:00 CST 2019, time=2019-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986372, encodeId=6ed419863e225, content=<a href='/topic/show?id=f3f1e0930ed' target=_blank style='color:#2F92EE;'>#病毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70930, encryptionId=f3f1e0930ed, topicName=病毒性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 14 18:01:00 CST 2018, time=2018-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032116, encodeId=31c720321162f, content=<a href='/topic/show?id=9952e912290' target=_blank style='color:#2F92EE;'>#综合干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79122, encryptionId=9952e912290, topicName=综合干预)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Jan 18 04:01:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336344, encodeId=3e0833634444, content=加强病毒性肝炎的管理。, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 11:12:43 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334830, encodeId=a31a33483062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Sun Jul 29 06:49:53 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-29 哈哈869

    学习了

    0

相关资讯

乙肝“小三阳”真的能转阴吗?

前几天听起同事聊他工作上遇到的一个“怪事”,有位门诊病人之前在我们医院做的乙肝两对半是HBsAg、HBeAb、HBcAb三项阳性的“小三阳”,这几天来复查做出来的却只有HBsAb阳性。会不会护士抽错人了?于是同事通知病人带着身份证前来重新抽血复查,最终结果还是只有HBsAb阳性,最后同事只能将结果发出了。大家是不是怀疑是实验操作不当、试剂过期、试剂被污染或者标本被污染等原因呢?笔者刚开始也是这

慢性乙肝肝硬化如何治疗 经典病例告诉您

患者于20年前健康查体发现HBV感染,肝功能异常,无纳差、乏力、恶心、腹胀等不适,给予保肝治疗后,肝功能正常。此后定期复查肝功各项指标均在正常范围,HBV-DNA定量未查。于两年前复查肝功能异常,HBV-DNA定量阳性,予“拉米夫定片”及保肝治疗,肝功能正常,HBV-DNA定量阴性。1年前停服“拉米夫定片”后肝功能又出现异常,HBV-DNA定量阳性,给予“拉米夫定片”及“阿德福韦酯片”联合治疗,病

“小三阳”患者怎样摆脱乙肝病魔?

《慢性乙型肝炎防治指南》(2015年版)指出,以下患者应用聚乙二醇干扰素(Peg IFN-α)可获得较高的疗效:①HBV DNA<2×108 IU/ml;②高ALT 水平;③ 基因型为A 或B 型;④基线低HBsAg水平;⑤肝组织炎症坏死G2 以上;HBeAg 阴性慢乙肝患者还无有效的治疗前预测病毒学应答的因素。在有抗病毒指征的患者中,相对年轻的患者(包括青少年患者)、希望近年内生育的患者、期望短

J Hepatol:终于等到你 免疫耐受乙肝儿童或可试试这种疗法

儿童中慢性乙肝病毒(HBV)感染,一生中进展为肝硬化或肝癌的风险要显著高于普通人,是全世界一个严重的健康问题。目前指南推荐,慢性HBV儿童患者,应首选保守治疗,并仔细评估治疗反应。干扰素是首选药物,而核苷酸类似物是二线治疗药物。

J Infection:婴儿期广泛接种乙肝疫苗大有裨益

2018年6月,发表在《J Infect》的一项由中国香港研究者进行的研究表明,30年的新生儿疫苗接种已经大幅降低了该项目覆盖的孕妇乙型肝炎病毒感染的产前患病率。

临床治愈,一生一试:乙肝患者争取治愈的希望能实现吗?

我国《慢性乙型肝炎(CHB)防治指南》(2015年版)指出,HBeAg阳性与HBeAg阴性患者,停药后获得持久的HBsAg消失,伴或不伴HBsAg血清学转换是理想的终点。标志着CHB完全缓解,长期结局改善,患者达到临床治愈。这一吸引人的终点是每例CHB患者渴望达到的,而这一需求如何满足则是对临床医生的挑战。